Full Text
PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia

Abstract

Authors

T.T.T. Nguyen R. Yagudina A. Kulikov

Back to Volume 14, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×